Presence of insulin-like growth factor binding proteins correlates with tumor-promoting effects of matrix metalloproteinase 9 in breast cancer

Neoplasia (United States)

Volumn 17, Issue 5, 2015, Pages 421-433

  Park, Jae Hyun ^a   Rasch, Morten Grønbech ^a,b   Qiu, Jing ^a   Lund, Ida Katrine ^b   Egeblad, Mikala ^a,c  

^a Simons Center for Quantitative Biology   (United States)

^b FINSEN LABORATORY   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; SOMATOMEDIN BINDING PROTEIN 1; VIRUS LARGE T ANTIGEN; IGFBP1 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; INTERCROPPING; MOUSE; MOUSE MAMMARY TUMOR VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN VIRUS 40; TRIPLE NEGATIVE BREAST CANCER; TUMOR PROMOTION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; POLYOMAVIRUS INFECTION; PROTEIN MICROARRAY; RETROVIRUS INFECTION; VIRUS INFECTION;

ANIMALS; ANTIGENS, VIRAL, TUMOR; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; KAPLAN-MEIER ESTIMATE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; POLYOMAVIRUS INFECTIONS; PROTEIN ARRAY ANALYSIS; RETROVIRIDAE INFECTIONS; SIMIAN VIRUS 40; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR VIRUS INFECTIONS;

EID: 84943173385     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.04.003     Document Type: Article

References (58)

1. Davoli A, Hocevar BA, and Brown TL (2010). Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 65, 611-623.
2. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, and Harbeck N (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol 20, 1913-1927.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, and Akslen LA, et al (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
4. Weigelt B and Reis-Filho JS (2009). Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6, 718-730.
5. Guy CT, CardiffRD, and Muller WJ (1992). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-961.
6. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, and Chandrasekharan S, et al (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8, R76.
7. Maroulakou IG, Anver M, Garrett L, and Green JE (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci U S A 91, 11236-11240.
8. Bennett CN and Green JE (2010). Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. Toxicol Pathol 38, 88-95.
9. CardiffRD (2003). Mouse models of human breast cancer. Comp Med 53, 250-253.
10. Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, Peeters G, Krummel MF, and Werb Z (2008). Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech 1, 155-167.
11. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, and Pollard JW (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66, 11238-11246.
12. Egeblad M, Nakasone ES, and Werb Z (2010). Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18, 884-901.
13. Egeblad M, Rasch MG, and Weaver VM (2010). Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol 22, 697-706.
14. Rajaram M, Li J, Egeblad M, and Powers RS (2013). System-wide analysis reveals a complex network of tumor-fibroblast interactions involved in tumorigenicity. PLoS Genet 9, e1003789.
15. Brown PD (2000). Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 9, 2167-2177.
16. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gansbacher B, and Schmitt M (2001). Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61, 1272-1275.
17. Whittaker M, Floyd CD, Brown P, and Gearing AJ (1999). Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99, 2735-2776.
18. Kessenbrock K, Plaks V, and Werb Z (2010). Matrix metalloproteinases: proteolytic regulators of the tumor microenvironment. Cell 141, 52-67.
19. Coussens LM, Fingleton B, and Matrisian LM (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
20. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, and Werb Z, et al (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2, 737-744.
21. Egeblad M and Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
22. Coussens LM, Tinkle CL, Hanahan D, and Werb Z (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490.
23. Giraudo E, Inoue M, and Hanahan D (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114, 623-633.
24. Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, and Fingleton B (2008). Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68, 6251-6259.
25. Nozawa H, Chiu C, and Hanahan D (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103, 12493-12498.
26. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, and Werb Z (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411-422.
27. Rasch MG, Lund IK, Illemann M, Hoyer-Hansen G, and Gardsvoll H (2010). Purification and characterization of recombinant full-length and protease domain of murine MMP-9 expressed in Drosophila S2 cells. Protein Expr Purif 72, 87-94.
28. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, and Qiu J, et al (2012). Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503.
29. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, and Klaar S, et al (2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7, R953-964.
30. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, and Yu J, et al (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679.
31. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, and Haibe-Kains B, et al (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98, 262-272.
32. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, and Liu ET, et al (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102, 13550-13555.
33. Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, and Lawson DA, et al (2012). The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov 2, 638-651.
34. Camp RL, Dolled-Filhart M, and Rimm DL (2004). X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10, 7252-7259.
35. Allavena P, Germano G, Marchesi F, and Mantovani A (2011). Chemokines in cancer related inflammation. Exp Cell Res 317, 664-673.
36. Pollard JW (2009). Trophic macrophages in development and disease. Nat Rev Immunol 9, 259-270.
37. Murdoch C, Muthana M, Coffelt SB, and Lewis CE (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8, 618-631.
38. Ahn GO and Brown JM (2008). Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13, 193-205.
39. Coppock HA, White A, Aplin JD, and Westwood M (2004). Matrix metalloprotease-3 and-9 proteolyze insulin-like growth factor-binding protein-1. Biol Reprod 71, 438-443.
40. Lee SE, Han BD, Park IS, Romero R, and Yoon BH (2008). Evidence supporting proteolytic cleavage of insulin-like growth factor binding protein-1 (IGFBP-1) protein in amniotic fluid. J Perinat Med 36, 316-323.
41. Firth SM and Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23, 824-854.
42. Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J, DiAugustine RP, Barrett JC, Afshari CA, and Dunn SE (2002). Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 4, 204-217.
43. Larsen PH, DaSilva AG, Conant K, and Yong VW (2006). Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and-12 null mice. J Neurosci 26, 2207-2214.
44. Nishijima T, Piriz J, Duflot S, Fernandez AM, Gaitan G, Gomez-Pinedo U, Verdugo JM, Leroy F, Soya H, and Nunez A, et al (2010). Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 67, 834-846.
45. Prudova A, Auf Dem Keller U, Butler GS, and Overall CM (2010). Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics 9, 894-911.
46. Rorive S, Berton A, D'Haene N, Takacs CN, Debeir O, Decaestecker C, and Salmon I (2008). Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth andmotility in astrocytomas. Glia 56, 1679-1690.
47. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, and Ou ZL, et al (2004). Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88, 75-85.
48. Song J, Su H, Zhou YY, and Guo LL (2013). Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev 14, 1615-1621.
49. HuffKK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, and Dickson RB (1986). Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46, 4613-4619.
50. Sparmann A and Bar-Sagi D (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458.
51. Ancrile B, Lim KH, and Counter CM (2007). Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21, 1714-1719.
52. Yang G, Rosen DG, Zhang Z, Bast Jr RC, Mills GB, Colacino JA, Mercado-Uribe I, and Liu J (2006). The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103, 16472-16477.
53. Webster GA and Perkins ND (1999). Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19, 3485-3495.
54. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, and Kuprash DV, et al (2005). p53 is a suppressor of inflammatory response in mice. FASEB J 19, 1030-1032.
55. Deryugina EI, Zajac E, Juncker-Jensen A, Kupriyanova TA, Welter L, and Quigley JP (2014). Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia 16, 771-788.
56. Ardi VC, Kupriyanova TA, Deryugina EI, and Quigley JP (2007). Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 104, 20262-20267.
57. Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Deryugina EI, and Quigley JP (2009). Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway. J Biol Chem 284, 25854-25866.
58. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, and Dano K (1997). Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 77, 345-355.